Worth to remember when using pain killers Review article
Article Sidebar
Published:
Jun 30, 2014
Keywords:
non-steroidal anti-inflammatory drugs, COX-1, COX-2, cardiovascular risk
Main Article Content
Abstract
Non-steroidal anti-inflammatory drugs are one of the most commonly used group of drugs in general. Event OTC drugs however can be dangerous. Overuse of NSAIDs can lead to renal, gastric, cerebral or cardiovascular damage. In this article safety use of NSAIDs crucial aspects have been reviewed.
Article Details
How to Cite
Dawidek, M., Kowalewski, S., Wełnicki , M., & Mamcarz , A. (2014). Worth to remember when using pain killers. Medycyna Faktow (J EBM), 7(2(23), 74-78. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2371
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Grosser T., Fries S., Fitzgerald G.A.: Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 2006; 116: 4-15.
2. Abraham N.S., El-Serag H.B., Hartman C. et al.: Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment. Pharmacol. Ther. 2007; 25: 913-924.
3. Puszczewicz M.: Niesteroidowe leki przeciwzapalne. Przew. Lek. 2007; 3: 32-38.
4. Woroń J., Filipczak-Bryniarska I., Wordliczek J.: Nieopioidowe leki przeciwbólowe w farmakoterapii bólu. W: Kompendium leczenia bólu. Malec-Milewska M., Woroń J. (red.). Wyd. 1. Medical Education Sp. z o.o., Warszawa 2012.
5. Burke A., Smyth E., FitzGerald G.A.: Leki przeciwbólowe-przeciwgorączkowe; farmakoterapia dny moczanowej. W: Farmakoterapia Goodmana & Gilmana. Laurence L. Bruton, John S. Lazo, Keith. L. Parker. Wyd. I. CZELEJ Sp. z o.o. Lublin 2007.
6. Capone M.L., Tacconelli S., Sciulli M.G. et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and lowdose aspirin in healthy subjects. Circulation 2004; 109: 1468-1471.
7. Garcia Rodriguez L.A., Varas-Lorenzo C., Maguire A., Gonzales-Perez A.: Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006.
8. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2012; 33: 1635-1701.
9. Strand V.: Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370: 2138-2151.
10. Graham D.J.: COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk - The Seduction of Common Sense. JAMA. published online Sep 12: 2006; (DOI:10.1001/jama.296.13.jed60058).
11. Bresalier R.S., Sandler R.S., Quan H. et al.: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N. Engl. J. Med. 2006; 355: 221]. N. Engl. J. Med. 2005; 352: 1092-1102.
12. Catella-Lawson F., Reilly M.P., Kapoor S.C. et al.: Cyclo-oxygenase inhibitors and the anti-platelet effect of aspirin. New Engl. J. Med. 2001; 345: 1809-1817.
13. Meek I.L., Vonkeman H.E., Kasemier J. et al.: Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur. J. Clin. Pharmacol. DOI: 10.1007/s00228-012-1370-y.
14. Awa K., Satoh H., Hor S., Sawada Y.: Prediction of timedependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J. Clin. Pharm. Ther. 2012; 37: 469-474.
15. McGettigan P., Henry D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
16. McGettigan P., Henry D.: Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med. 2011; 8(9): 1-18.
17. Watson D.J., Rhodes T., Cai B. et al.: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 2002; 162: 1105-1110.
18. Varas-Lorenzo C., Riera-Guardia N., Calingaert B. et al.: Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidem., Drug Safe. 2011; 20: 1225-1236.
2. Abraham N.S., El-Serag H.B., Hartman C. et al.: Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment. Pharmacol. Ther. 2007; 25: 913-924.
3. Puszczewicz M.: Niesteroidowe leki przeciwzapalne. Przew. Lek. 2007; 3: 32-38.
4. Woroń J., Filipczak-Bryniarska I., Wordliczek J.: Nieopioidowe leki przeciwbólowe w farmakoterapii bólu. W: Kompendium leczenia bólu. Malec-Milewska M., Woroń J. (red.). Wyd. 1. Medical Education Sp. z o.o., Warszawa 2012.
5. Burke A., Smyth E., FitzGerald G.A.: Leki przeciwbólowe-przeciwgorączkowe; farmakoterapia dny moczanowej. W: Farmakoterapia Goodmana & Gilmana. Laurence L. Bruton, John S. Lazo, Keith. L. Parker. Wyd. I. CZELEJ Sp. z o.o. Lublin 2007.
6. Capone M.L., Tacconelli S., Sciulli M.G. et al.: Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and lowdose aspirin in healthy subjects. Circulation 2004; 109: 1468-1471.
7. Garcia Rodriguez L.A., Varas-Lorenzo C., Maguire A., Gonzales-Perez A.: Non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-3006.
8. European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal 2012; 33: 1635-1701.
9. Strand V.: Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet 2007; 370: 2138-2151.
10. Graham D.J.: COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk - The Seduction of Common Sense. JAMA. published online Sep 12: 2006; (DOI:10.1001/jama.296.13.jed60058).
11. Bresalier R.S., Sandler R.S., Quan H. et al.: Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [published correction appears in N. Engl. J. Med. 2006; 355: 221]. N. Engl. J. Med. 2005; 352: 1092-1102.
12. Catella-Lawson F., Reilly M.P., Kapoor S.C. et al.: Cyclo-oxygenase inhibitors and the anti-platelet effect of aspirin. New Engl. J. Med. 2001; 345: 1809-1817.
13. Meek I.L., Vonkeman H.E., Kasemier J. et al.: Interference of NSAIDs with the thrombocyte inhibitory effect of aspirin: A placebo-controlled, ex vivo, serial placebo-controlled serial crossover study. Eur. J. Clin. Pharmacol. DOI: 10.1007/s00228-012-1370-y.
14. Awa K., Satoh H., Hor S., Sawada Y.: Prediction of timedependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamic model. J. Clin. Pharm. Ther. 2012; 37: 469-474.
15. McGettigan P., Henry D.: Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-1644.
16. McGettigan P., Henry D.: Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. PLoS Med. 2011; 8(9): 1-18.
17. Watson D.J., Rhodes T., Cai B. et al.: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch. Intern. Med. 2002; 162: 1105-1110.
18. Varas-Lorenzo C., Riera-Guardia N., Calingaert B. et al.: Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidem., Drug Safe. 2011; 20: 1225-1236.